Meng Lee, MD; Jeffrey L. Saver, MD; Keun-Sik Hong, MD, PhD; Neal M. Rao, MD; Yi-Ling Wu, MS; Bruce Ovbiagele, MD, MS
Financial Support: Dr. Lee was supported by grant CMRPG6B0111 from Chang Gung Memorial Hospital. Dr. Saver was supported by SPOTRIAS (Specialized Programs of Translational Research in Acute Stroke) award P50 NS044378 from the National Institutes of Health. Dr. Ovbiagele was supported by grant U01 NS079179 from the National Institutes of Health.
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2954.
Corresponding Author: Bruce Ovbiagele, MD, MSc, Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB 301, MSC 606, Charleston, SC 29425-6160.
Current Author Addresses: Dr. Lee and Ms. Wu: Department of Neurology, Chang Gung University College of Medicine, Chang Gung Memorial Hospital, 6 West Sec., Chiapu Road, Puzi City, Chiayi County, Taiwan.
Drs. Saver and Rao: UCLA Stroke Center, 710 Westwood Boulevard, Los Angeles, CA 90095.
Dr. Hong: Department of Neurology, Ilsan Paik Hospital, 2240 Daewha-dong, Ilsanseo-gu, Goyang, South Korea.
Dr. Ovbiagele: Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB 301, MSC 606, Charleston, SC 29425-6160.
Author Contributions: Conception and design: M. Lee, B. Ovbiagele.
Analysis and interpretation of the data: M. Lee, J.L. Saver, K. Hong, N.M. Rao, Y. Wu, B. Ovbiagele.
Drafting of the article: M. Lee, J.L. Saver, K. Hong, N.M. Rao, B. Ovbiagele.
Critical revision of the article for important intellectual content: M. Lee, J.L. Saver, K. Hong, N.M. Rao, B. Ovbiagele.
Final approval of the article: M. Lee, J.L. Saver, K. Hong, B. Ovbiagele.
Provision of study materials or patients: M. Lee.
Statistical expertise: M. Lee, Y. Wu.
Obtaining of funding: M. Lee.
Administrative, technical, or logistic support: M. Lee, B. Ovbiagele.
Collection and assembly of data: M. Lee, K. Hong.
Lee M, Saver JL, Hong K, Rao NM, Wu Y, Ovbiagele B. Risk–Benefit Profile of Long-Term Dual- Versus Single-Antiplatelet Therapy Among Patients With Ischemic Stroke: A Systematic Review and Meta-analysis. Ann Intern Med. 2013;159:463-470. doi: 10.7326/0003-4819-159-7-201310010-00006
Download citation file:
Published: Ann Intern Med. 2013;159(7):463-470.
Dual-antiplatelet regimens for prevention of recurrent stroke promote antithrombotic effects but may increase the risk for hemorrhage.
To qualitatively and quantitatively examine the risk for recurrent stroke and intracranial hemorrhage (ICH) linked to long-term dual- and single-antiplatelet therapy among patients with ischemic stroke and transient ischemic attack.
PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials through March 2013 without language restrictions.
The search identified 7 randomized, controlled trials that involved a total of 39 574 participants and reported recurrent stroke and ICH as outcome measures.
All data from eligible studies were independently abstracted by 2 investigators according to a standard protocol.
Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0.89 [95% CI, 0.78 to 1.01]) or clopidogrel monotherapy (RR, 1.01 [CI, 0.93 to 1.08]). Risk for ICH did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (RR, 0.99 [CI, 0.70 to 1.42]) but was greater among patients receiving dual-antiplatelet therapy than among those receiving clopidogrel monotherapy (RR, 1.46 [CI, 1.17 to 1.82]).
Agents used in dual- and single-antiplatelet therapies varied across trials, and the relatively modest number of trials limited subgroup analysis.
Compared with monotherapy, dual-antiplatelet therapy lasting more than 1 year after an index ischemic stroke or transient ischemic attack is not associated with a greater reduction in overall recurrent stroke risk. However, long-term dual-antiplatelet therapy is linked to higher risk for ICH than clopidogrel monotherapy in this patient population.
Chang Gung Memorial Hospital.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only